|
English
|
正體中文
|
简体中文
|
2823024
|
|
???header.visitor??? :
30248214
???header.onlineuser??? :
679
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"qin s k"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
|
Kojima T.;Shah M.A.;Muro K.;Francois E.;Adenis A.;Chih-Hung Hsu;Doi T.;Moriwaki T.;Kim S.-B.;Lee S.-H.;Bennouna J.;Kato K.;Shen L.;Enzinger P.;Qin S.-K.;Ferreira P.;Chen J.;Girotto G.;De La Fouchardiere C.;Senellart H.;Al-Rajabi R.;Lordick F.;Wang R.;Suryawanshi S.;Bhagia P.;Peter Kang S.;Metges J.-P.;Keynote-181 Investigators; Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
|
Kojima T.;Shah M.A.;Muro K.;Francois E.;Adenis A.;Chih-Hung Hsu;Doi T.;Moriwaki T.;Kim S.-B.;Lee S.-H.;Bennouna J.;Kato K.;Shen L.;Enzinger P.;Qin S.-K.;Ferreira P.;Chen J.;Girotto G.;De La Fouchardiere C.;Senellart H.;Al-Rajabi R.;Lordick F.;Wang R.;Suryawanshi S.;Bhagia P.;Peter Kang S.;Metges J.-P.;Keynote-181 Investigators; Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
|
Satoh T.;Doi T.;Ohtsu A.;Tsuji A.;Omuro Y.;Mukaiyama A.;Kobayashi M.;Miwa H.;Xu R.-H.;Sun G.-P.;Xu J.-M.;Wang J.-W.;Li J.;Qin S.-K.;Feng J.-F.;Chung H.C.;Bang Y.-J.;Chung I.-J.;Kun-Huei Yeh; Satoh T.; Doi T.; Ohtsu A.; Tsuji A.; Omuro Y.; Mukaiyama A.; Kobayashi M.; Miwa H.; Xu R.-H.; Sun G.-P.; Xu J.-M.; Wang J.-W.; Li J.; Qin S.-K.; Feng J.-F.; Chung H.C.; Bang Y.-J.; Chung I.-J.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
|
Satoh T.;Doi T.;Ohtsu A.;Tsuji A.;Omuro Y.;Mukaiyama A.;Kobayashi M.;Miwa H.;Xu R.-H.;Sun G.-P.;Xu J.-M.;Wang J.-W.;Li J.;Qin S.-K.;Feng J.-F.;Chung H.C.;Bang Y.-J.;Chung I.-J.;Kun-Huei Yeh; Satoh T.; Doi T.; Ohtsu A.; Tsuji A.; Omuro Y.; Mukaiyama A.; Kobayashi M.; Miwa H.; Xu R.-H.; Sun G.-P.; Xu J.-M.; Wang J.-W.; Li J.; Qin S.-K.; Feng J.-F.; Chung H.C.; Bang Y.-J.; Chung I.-J.; KUN-HUEI YEH |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
